Last reviewed · How we verify
Ketorolac Oral Tablet [Toradol]
Ketorolac inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain.
Ketorolac inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain. Used for Moderate to severe acute pain (short-term use), Postoperative pain.
At a glance
| Generic name | Ketorolac Oral Tablet [Toradol] |
|---|---|
| Also known as | Toradol |
| Sponsor | Montefiore Medical Center |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID) |
| Target | COX-1 and COX-2 |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | Phase 3 |
Mechanism of action
As a nonsteroidal anti-inflammatory drug (NSAID), ketorolac blocks both COX-1 and COX-2 enzymes, which are responsible for producing prostaglandins that mediate inflammation, pain, and fever. By reducing prostaglandin levels, ketorolac provides rapid analgesic and anti-inflammatory effects. It is typically used for short-term management of moderate to severe acute pain.
Approved indications
- Moderate to severe acute pain (short-term use)
- Postoperative pain
Common side effects
- Gastrointestinal upset (nausea, dyspepsia)
- Headache
- Dizziness
- Renal impairment
- Gastrointestinal bleeding
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ketorolac Oral Tablet [Toradol] CI brief — competitive landscape report
- Ketorolac Oral Tablet [Toradol] updates RSS · CI watch RSS
- Montefiore Medical Center portfolio CI